Literature DB >> 12647645

A case of refractory Henoch-Schönlein purpura treated with thalidomide.

Soo Jeong Choi1, Sung Kyu Park, Wan Sik Uhm, Dae Sik Hong, Hee Sook Park, Young Lip Park, Kye Won Kwon.   

Abstract

Henoch-Schönlein purpura is an acute, self-limited vasculitis syndrome which shows characteristic skin, joint, renal and gastrointestinal manifestations. It is common in childhood and may also occur in adults with fatal complications such as nephritis and gastrointestinal bleeding. We experienced a case of a 20-year-old woman who presented with palpable purpura and severe arthritis. The histopathologic examination of the skin revealed leukocytoclastic vasculitis with perivascular deposition of IgA and she was diagnosed with Henoch-Schönlein purpura. Despite treatment with prednisolone for one month, she had more aggravated purpura and fatal gastrointestinal bleeding. The symptoms were improved shortly by cyclophosphamide pulse therapy with plasmapheresis but symptoms were aggravated and symmetric mononeuropathy of the ulnar nerve developed. She was treated with 400 mg/day of thalidomide and symptoms were improved. We herein report a case of Henoch-Schönlein purpura successfully treated with thalidomide which was refractory to prednisolone, immunosuppressive drugs and plasmapheresis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12647645      PMCID: PMC4531694          DOI: 10.3904/kjim.2002.17.4.270

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  20 in total

1.  Adult Henoch-Schönlein purpura with fatal complications.

Authors:  R McCarthy; T Rosen; S H Chen; S S Raimer
Journal:  Arch Dermatol       Date:  2001-01

Review 2.  Henoch-Schönlein purpura.

Authors:  F T Saulsbury
Journal:  Curr Opin Rheumatol       Date:  2001-01       Impact factor: 5.006

3.  Thalidomide for chronic GVHD.

Authors:  P S Sastry; R L Powles
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

Review 4.  Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature.

Authors:  F T Saulsbury
Journal:  Medicine (Baltimore)       Date:  1999-11       Impact factor: 1.889

5.  Life-threatening gastrointestinal bleeding due to a jejunal lesion of Henoch-Schönlein purpura.

Authors:  F Lippl; W Huber; M Werner; H Nekarda; H Berger; N Weigert
Journal:  Endoscopy       Date:  2001-09       Impact factor: 10.093

6.  IgA1 is the major IgA subclass in cutaneous blood vessels in Henoch-Schönlein purpura.

Authors:  C A Egan; T B Taylor; L J Meyer; M J Petersen; J J Zone
Journal:  Br J Dermatol       Date:  1999-11       Impact factor: 9.302

Review 7.  Thalidomide and its dermatologic uses.

Authors:  M Moraes; G Russo
Journal:  Am J Med Sci       Date:  2001-05       Impact factor: 2.378

8.  Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature.

Authors:  A L Belman; C R Leicher; S L Moshé; A P Mezey
Journal:  Pediatrics       Date:  1985-04       Impact factor: 7.124

9.  Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome.

Authors:  R Blanco; V M Martínez-Taboada; V Rodríguez-Valverde; M García-Fuentes; M A González-Gay
Journal:  Arthritis Rheum       Date:  1997-05

10.  Massive gastric hemorrhage: an unusual complication of Henoch-Schönlein purpura.

Authors:  T R Weber; J L Grosfeld; J Bergstein; J Fitzgerald
Journal:  J Pediatr Surg       Date:  1983-10       Impact factor: 2.545

View more
  2 in total

Review 1.  Multisystemic manifestations of IgA vasculitis.

Authors:  Lina Du; Panpan Wang; Chang Liu; Shaojing Li; Shuang Yue; Yan Yang
Journal:  Clin Rheumatol       Date:  2020-06-16       Impact factor: 2.980

2.  Intestinal infarction and portal vein thrombosis in a patient with henoch schonlein purpura.

Authors:  Mekdess Abebe; Asha Patnaik; Frederick Miller; Heidi Roppelt; Nand K Wadhwa; Mersema Abate; Edward P Nord
Journal:  Case Rep Rheumatol       Date:  2012-10-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.